Halia Therapeutics Appoints Paul Jones as New Chief Strategy Officer

Halia Therapeutics has announced the appointment of Paul Jones as its new Chief Strategy Officer and General Manager for International Markets, a role designed to enhance the company’s strategic focus on resilience-based therapeutic development. This appointment, made public on October 6, 2025, aligns with Halia’s efforts to advance its proprietary platform, GENMOR-AI, which utilizes artificial intelligence to identify genetic modifiers of disease.

In his new position, Jones will play a crucial role in bolstering Halia’s partnership with the Department of Health – Abu Dhabi. The collaboration aims to harness the Emirati Genome dataset to uncover genetic resilience factors that can help protect individuals from various diseases. David Bearss, Ph.D., CEO of Halia Therapeutics, expressed enthusiasm for Jones’s appointment, stating, “His proven track record in large-scale genomics initiatives—from the UK’s 100,000 Genomes Project to the Emirati Genome Programme—makes him an exceptional addition to our leadership team.”

Jones comes to Halia with over 30 years of experience in the life sciences sector. His background includes significant accomplishments in genomics, digital health transformation, and precision medicine. Before joining Halia, he served as CEO of the Omics Centre of Excellence at M42, a tech-enabled health company based in Abu Dhabi, where he was instrumental in advancing the Emirati Genome Program—one of the largest genomics initiatives globally. His previous positions include roles at Illumina and Genomics England, where he contributed to the successful delivery of the landmark 100,000 Genomes Project.

Jones’s expertise is expected to further enhance Halia’s focus on its APOE4 program, which investigates individuals carrying the highest-risk genetic variant for Alzheimer’s disease who do not develop the condition. By utilizing GENMOR-AI on extensive genomic datasets, Halia strives to identify resilience mechanisms that could guide the creation of new therapies for neurodegenerative diseases, metabolic disorders, cardiovascular diseases, and cancer.

“I’m excited to join Halia at this pivotal moment,” said Paul Jones. “The company’s unique focus on genetic resilience—rather than just disease risk—represents the next frontier in precision medicine. By combining cutting-edge AI with strategic global partnerships, Halia is positioned to revolutionize drug discovery and patient outcomes.”

Halia Therapeutics focuses on addressing the root causes of inflammation through innovative therapeutic solutions. The company employs genetic insights and AI-enabled discovery to build a pipeline of novel therapies targeting inflammatory pathways associated with various diseases, including metabolic disorders and neurodegeneration. The firm is headquartered in Lehi, Utah, and is actively pursuing global partnerships in clinical research, drug discovery, and personalized medicine.

For more information, visit Halia’s official website at www.haliatx.com or connect with them on LinkedIn and Twitter @HaliaTx.

For media inquiries, contact Taylor Avei, Director of Business Development at Halia Therapeutics, via email at [email protected] or call +1 (385) 355-4315. Additionally, Leigh Salvo from New Street Investor Relations can be reached at [email protected] for investor-related questions.